Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

St. Augustinus Hospital, Wilrijk

University Hospital Antwerp (UZA), Edegem

CHU APHM la Timone / Aix Marseille University, Dermatology and Skin Cancer Department, Marseille

University Hospital Hamburg-Eppendorf, Hamburg

Inova Schar Cancer Institute, Fairfax

MD Anderson International Cancer Center Spain, Madrid

Regional University Hospital of Malaga, Málaga

Orlando Health, Inc., Orlando

Sylvester Comprehensive Cancer Center, Miami

H. Lee Moffitt Cancer Center & Research Institute, Tampa

University Clinical Hospital of Salamanca, Salamanca

University Hospital Center of Grenoble Alpes, Department of Dermatology, Grenoble

University Duisburg-Essen, University Hospital Essen, Department of Dermatology, Essen

Frankfurt University Clinic, Department of Dermatology, Venereology and Allergology, Frankfurt

South Lyon Hospital Center, Lyon

University Hospital Tuebingen, Department of Dermatology, Tübingen

St. Louis Hospital, Paris

Anschutz Cancer Pavilion, Aurora

University Hospital Center of Poitiers, Department of Oncology, Poitiers

University Hospital Erlangen, Department of Dermatology, Erlangen

UC San Diego Moores Cancer Center, La Jolla

University Hospital Regensburg, Clinic and Policlinic for Dermatology, Regensburg

University Hospital Leipzig, Department of Dermatology, Venereology and Allergology, Leipzig

University Hospital Vall d'Hebron, Barcelona

ICO Hospitalet, Barcelona